DRUG
NNC0662-0419
NNC0662-0419 will be administered subcutaneously.
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Status
Recruiting
Phase
Phase 2
Enrollment
230
Locations
25
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.
Interventions
Treatment arms and agents.
DRUG
Semaglutide
Semaglutide will be administered subcutaneously.
DRUG
NNC0662-0419 Placebo
Placebo matched to NNC0662-0419 will be administered subcutaneously.
DRUG
Semaglutide placebo
Placebo matched to semaglutide will be administered subcutaneously.
Timeline
From registration to results.
First posted
Jun 10, 2026
Study start
Jun 9, 2026
Primary completion
Jul 12, 2027
Study completion
Jul 12, 2027
Results posted
Not reported
Registry updated
Jul 10, 2026
Outcomes
What the study measures.
Primary outcomes
Number of gastrointestinal adverse events
Time frame · From week 0 to week 39
Measured as number of events.
Secondary outcomes
Relative change in body weight
Time frame · From week 0 to week 32
Measured as percentage (%) change.
Change in body mass index (BMI)
Time frame · From week 0 to week 32
Measured as kilogram per square meter (kg/m\^2).
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening. * Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening. * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus.
Study locations
25 registered sites.
Puerto Rico · United States. Showing up to 24 locations stored in the fast local snapshot.
Chambliss Clinical Trials, LLC
Montgomery, Alabama, United States
FDRC
Costa Mesa, California, United States
Los Angeles Institute for Metabolic Research
Los Angeles, California, United States
Encore Medical Research LLC
Hollywood, Florida, United States
South Broward Research LLC
Miramar, Florida, United States
West Orange Endocrinology
Ocoee, Florida, United States
Cedar-Crosse Research Center
Chicago, Illinois, United States
Great Lakes Clinical Trials
Chicago, Illinois, United States
Midwest Inst For Clin Res
Indianapolis, Indiana, United States
L-MARC Research Center
Louisville, Kentucky, United States
Endo And Metab Cons
Rockville, Maryland, United States
StudyMetrix Research LLC
City of Saint Peters, Missouri, United States
Great Lakes Medical Research
Westfield, New York, United States
KDCILM, LLC & Accellacare US, Inc.
Wilmington, North Carolina, United States
Family Practice Center of Wadsworth Inc.
Wadsworth, Ohio, United States
UPA Ctr Weight and Eating Dis
Philadelphia, Pennsylvania, United States
Clinical Res Collaborative
Cumberland, Rhode Island, United States
Holston Medical Group_Bristol
Bristol, Tennessee, United States
Holston Medical Group
Kingsport, Tennessee, United States
Clinical Research Associates
Nashville, Tennessee, United States
PlanIt Research, PLLC
Houston, Texas, United States
Pinnacle Clinical Research
San Antonio, Texas, United States
National Clin Res Inc.
Richmond, Virginia, United States
Rainier Clin Res Ctr Inc
Renton, Washington, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Semaglutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Fibrosis Lessens After Metabolic Surgery
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease
Oelisoa Andriankaja · Obesity · Dental Care for Children
Not applicable
Not yet recruiting
50
2026-07
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Terrestrial Bio, Inc. · Overweight and/or Obesity
Phase 1
Recruiting
62
2026-07
Tirzepatide Impact Assessment Study
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes
Phase 3
Completed
884
2026-07
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk · Obesity · Type 2 Diabetes
Phase 3
Recruiting
2,500
2026-07
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
Imperial College London · Pulmonary Arterial Hypertension
Phase 2
Not yet recruiting
32
2026-07
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
400
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.